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The aim of this retrospective study was to investigate the infection of hepatitis C virus (HCV) genotypes 
in hepatocellular carcinoma (HCC) patients from rural areas of Faisalabad region. Among 179 HCC 
subjects, men and women were 51 and 49%, respectively. All samples positive for HCV RNA by 
qualitative PCR were genotyped, applying genotype-specific PCR. They were confirmed using HCV 5’ 
non-coding region sequence analytical data. Major risk factor for HCC development and progression 
was identified to be chronic HCV. It was found among 56.5 ± 2.1 years of age. All these HCC cases were 
HCV-related and no case was linked with other types of viruses. Using genotype specific primers, HCV 
genotype 3a (55.3%) was significantly (P<0.0001) higher, followed by 3b (15.8%), 1 (9.24%), 4 (8.05%) 
and 2 (7.15%). Other genotypes, namely 5a and 6a were only 1.19 and 1.05% among the HCC patients. 
About 1.05% remained un-typed because of minute viral load. HCV genotype 3a was strongly linked 
with HCC, followed by 3b. Moreover, HCC was linked with liver cirrhosis (81%). It is suggested that 
genotyping may be recommended before starting interferon therapy.  
 





There are about 200 million patients with hepatitis C virus 
(HCV) in the world and three to four million individuals 
are diagnosed as new cases every year (Farshapour et 
al., 2010). Approximately 2.0, 2.7, 5.0 and 10.0 million 
cases are in Japan, the United States, Europe and 
Pakistan, respectively (Higuchi et al., 2002). HCV is a for-
midable cause of morbidity and mortality worldwide and 
has higher propensity for causing liver disease, leading to 
chronic hepatitis C. Chronic HCV infection may cause 
liver cirrhosis and hepatocellular carcinoma (HCC) over 
the course of 20 to 30 years if not cured timely. The in-
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in  Europe,  Japan,  North   America,   Pakistan   and 
Taiwan (Hamid et al., 2004; Kao and Chen, 2002). Thus, 
there is a dire need to understand the risk factors for 
HCC development and progression and most essentially 
to provide effective treatment for HCV in time to prevent 
its progression to the end-stage, that is, liver diseases 
and HCC.  
It is surmised that HCV genotypes may be related to 
disease progression. Therefore, further understanding of 
the clinical relevance and therapeutic implications of the 
HCV genotypes is crucial for designing personalized 
therapies for patients with chronic HCV infection. Recent 
molecular epidemiological studies have documented 
marked differences in genotype distribution by geogra-
phical regions and among different patient groups. Based 
on genetic differences between HCV isolates, the heap-
titis C virus is classified into six genotypes (Farshapour et  




al., 2010, Simmonds et al., 2005) with several subtypes 
within each genotype (represented by letters). Genotypes 
1, 2 and 3 are widely distributed (Farshapour et al., 2010) 
throughout the Asian countries (Japan, Taiwan, Thailand, 
India, Pakistan and China), Australia, Europe and the 
USA. Genotype 4 is predominantly confined to the Middle 
East, Central Africa and Egypt (Higuchi et al., 2002). 
Genotypes 5 and 6 are found mainly in South Africa and 
South East Asia, respectively (Hamid et al., 2004). The 
highest prevalence of HCV has been reported from Egypt 
(Frank et al., 2000).  
The global epidemiology of viral hepatitis A and 
hepatitis B is well established, but HCV data related with 
HCC remain limited in Pakistan (Tong et al., 1996; Kao 
and Chen, 2002; Hamid et al., 2004) because of ex-
penses involved in diagnosis. Determination of HCV 
genotypes is of clinical significance in assessing the drug 
responsiveness and prognosis of the HCC patients. 
Moreover, the HCV genotypes have epidemiologic 
significance as well, as they indicate transmission route 
of infection and have not received extensive studies in 
Pakistan, partly due to the expenses involved and partly 
due to practical difficulties involved in getting samples for 
the detection of HCV RNA in the serum of infected 
individuals. Further, large scale and long term follow-up 
studies are necessary to clarify the relationship between 
genotype and disease progression in different areas 
(Waheed et al., 2009) of each country. Other risk factors 
for disease progression and development of HCC are 
age at infection, diabetes, gender, hepatic fibrosis 
(particularly cirrhosis), host genetic factors, iron overload, 
greater degree of hepatic inflammation combined with 
steatosis, and viral load with its quasi-species (Waheed 
et al., 2009). In addition to these, other potential risk 
factors may include co-infection with HBV, or human 
immunodeficiency virus (HIV), smoking and obesity 
(Idrees et al., 2008; 2009). Peripheral viral load and viral 
genotypes were also reported to have impact on pro-
gression of disease. However, other authors found no 
association of the development of HCC with a particular 
HCV genotype (Ryu et al., 2009). Dissimilar genotypes of 
HCV have relation with epidemiological studies, clinical 
management of HCV infection, response rate to anti-viral 
treatment and effective vaccine development 
Patients living in rural areas cannot afford expensive 
medical checkups and go to the hospital only when their 
illness gets aggravated and become very weak. This 
study was carried out to find out the infection of HCV 
genotypes in HCC patients in rural population, asso-
ciation between particular HCV genotypes and HCC and 













from January 2006 to December 2009 (356 patients) in order to 
determine the true prevalence of HCC and chronic HCV and their 
possible association. Of these subjects, 179 satisfied the criteria for 
inclusion in this study: HCC was confirmed by liver imaging using 
ultra-sonography and computed tomography or histologically or 
chronic HCV was of any etiology. The diagnosis of liver cirrhosis 
was done mainly based on the histological evidence. All clinical 
records of these patients were checked to judge the etiology of 
HCC. Histological observations of liver tissue surrounding the 
cancer were also documented. Possible sources of transmission of 
disease and duration of blood-borne infectious hepatitis were also 
recorded. For calculation of time of transmission of HCV infection, 
time of first blood transfusion or first major/minor surgery was also 
recorded. Data on possible community routes of infection such as 
cautery, circumcision and tattooing as well as potential medical 
routes of infection such as history of taking different injections, 
history of previous hospitalization and surgical operations; dental 
procedures (e.g., tooth extraction/filling and gum treatment), and 
other invasive medical procedures (e.g., intravenous 
catheterization, abscess drainage, esophageal vortices, sclera-
therapy, pulmonary endoscopy, urinary catheteri-zation, upper or 
lower gastrointestinal endoscopy) were also recorded.  
Married women were also asked about their history of obstetric 
and gynecological interventions (e.g., cautery, curettage and 
dilatation, evacuation operations, healthcare provider, mode of 
delivery, place of delivery and handling person/s) as described 
previously (Frank et al., 2000). The research described in this work 
followed the tenets of the Declaration of Helsinki promulgated in 
1964 and was approved by the institutional human experimentation 
committee and PINUM.  
After informed consent, the subjects were asked to provide a 
blood sample for HCV testing during their visits to PINUM. All blood 
samples were screened for anti-HCV, anti-HBc, HBsAG, anti-
HBsAg, anti-HIV 1 and HIV 2 using ELISA kits (DRG Instruments, 
Germany) following the instructions of the manufacturers. Serum 
hepatitis B surface antigen (HBsAg) antibody or anti-HCV were 





10 ml of venous blood was collected from all the study subjects and 
sera were tested for liver function tests and HCV IgG antibody 
using antibody kit (Innogenetics, Ghent, Belgium). All respondents 
having ALT more than 100 IU/L were tested through ultra-
sonography and computed tomography.  
HCV samples collected from the respondents and their family 
members were also analyzed for HCV RNA using a previously 
validated, in-house-nested reverse transcriptase polymerase chain 
reaction as described previously (Kao and Chen, 2002). Fresh 
plasma samples, processed within 2 h of collection by venous 
puncture, were stored at -70°C, after the addition of guanidine 





All serological tests were performed as described previously (Idrees 
et al., 2009) using standard kits, following the instructions of the 
manufacturers. Liver function tests namely alanine amino 
trasnferase (ALT), aspartate amino transferase (AST), alkaline 
phosphatase (ALP), γ -glutamyl transpeptidase (GGT) and bilirubin 
levels of all patients were determined using an auto-analyzer as 
described previously (Bukhari et al., 2010; Idrees et al., 2009). 
Serum α-fetoprotein (AFP) concentration was estimated by 
chemiluminescent immunometric commercial diagnostic kit using 
immunoassay system (Diagniostic Products, Los Angeles, CA, 
USA).  




Table 1. Serological parameters* and etiology of HCC patients (n = 179) and chronic HCV control 
subjects (n = 177). 
  
Serological parameter Value in HCC patient Value in chronic HCV patient 
Female 88 (49) 88 (49.7) 
Age ± SD (year) 
55±2.2 (51, male) 35.5±5.5 (50.3) 
58±3.2 (49) 36.1±4.5 (49.7) 
ALT (IU/L) > 60 (49.0) ≈ 42±6.5 (100) 
AST (IU/L) >62 (40.2) ≈ 40±3.5 (100) 
ALP (IU/L) 150 (100) 37.5±4.5 (100) 
AFP (ng/L) 400 (99.2) 50±2.5 (100) 
GGT (U/L) 126.7 (65.2) 65±4.5 (100) 
Bilirubin (mg/dL) >1.5 (100) 0.5±0.05 (99) 
Anti-HCV positive alone  176 (98.3) 177 (100) 
HCV-RNA PCR +ve 169 (94.4) 170 (96) 
HIV  0 (100) 0 (100) 
Cirrhosis present 145 (81) 7 (4) 
 
*The serological predictors were all elevated than the cutoff value for each parameter.  
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; AFP, α -




Qualitative and quantitative detection and genotyping of HCV 
RNA 
 
RNA extraction was carried out employing a commercial viral RNA 
isolation kit (Qiagem, Germany) following the instructions of the 
manufacturers. HCV-RNA was transcribed into cDNA immediately 
using primers (see below). For molecular identification of HCV, 
nested-RT qualitative characterization was done. The following sets 
of primers from the 5' untranslated region of the viral genome were 
used to amplify the HCV RNA45: P1 (outer antisense): 5'-
CGACACTCCACCATAGAT-3'; P2 (outer sense), 5' GCTCATG 
GTGCACGGTCTA-3'; P3 (inner antisense): 5'-GTG CTGTGAGG 
AACTACTGTCT-3'; and P4 (inner sense): 5'- ACTCGCAAGCA 
CCCTATCA -3'.  
The primers and oligoprobes gotten were synthesized from 
Applied Bio-systems, USA. The amplified products were 
electrophoresed in a 1% agarose gel, stained with ethidium 
bromide, and recorded on a digital imager (Eagle Eye II, Strata-
gene, LaJolla, CA). Sequence analysis of amplified products was 
performed by a commercial company (Fermentas, Pakistan). Se-
quences of candidate isolates were aligned with representative 
sequence of each major genotype or subtype selected from the 
NCBI GenBank database. Phylogenetic analysis of HCV isolates 
was performed by constructing phylogenetic trees using the 
neighbour-joining method, using the bootstrap re-sampling test. 
HCV RNA was quantitatively determined using a real-time PCR 
employing HCV RNA quantitative kit (Roche Amplicor HCV Monitor 





Statistical analysis was carried out for the study using GraphPad 





Biochemical, demographic  and  clinical  data  of  patients  
are presented in Table 1. 179 respondents who tested 
HCV seropositive and HCV-RNA PCR-positive at enroll-
ment, were included in this analysis. A total number of 91 
(51.0%) were males, and 2 were aged 24 ± 10 years. 
Overall, 99.9% were aged 56.5 ± 2.1 (Table 1). We used 
177 subjects as chronic HCV controls who also tested 
HCV sero-positive on enrolment. Their demographic, bio-
chemical and clinical data are shown in Table 1. 
All HCC patients had elevated level of serum bilirubin 
(>14.2 µmol/L) and ALP (>150 IU/L). In all the patients 
with HCC, ALT (>60 IU/L) and AST (>62 IU/L) levels 
were abnormal in 49.0 and 40.2% of HCC patients. AFP 
and GGT levels were abnormal in 99.2 and 65.2% pa-
tients suffering from HCC, respectively. Hepatic cirrhosis 
was found in 81% patients with HCC. All the patients 
were negative for anti-HIV 1 and anti-HIV 2 on enroll-
lment. All HCC patients had significantly higher values of 
all serological parameters and it is a normal trend.  
Among the 179 patients suffering from HCC, HCV anti-
bodies were detected in 176 (98.3%) serum samples. 
Three patients were found tissue-positive by PCR but 
they did not carry anti-HCV antibodies. Of these HCC pa-
tients with chronic HCV, 51% were male and 49% were 
females. All the HCC patients had past history of chronic 
HCV infection. 21 of them had also cholecystitis. Load of 
peripheral HCV RNA varied from 2.5 x 10
3
 to 5.4 x 10
7
 
copies/ml. We did not find significant difference (P<0.235) 
between HCV load in serum samples and tissue samples 
of the same HCC patients. Also, neither from PCR analy-
sis nor from anti-bodies or serological records, could we 
find any etiological information about the two patients, 
and they remained un-typed. They fell in the age range of 
24 ± 10 years. This infection did not follow  general  crite- 




Table 2. Distribution of HCV genotypes in HCC 
men and women patients. 
  
Genotype Men Women Total (%)* 
3a 49 50 99 (55.30
a
) 
3b 13 15 28 (15.80
b
) 
1 7 9 16 (9.24
c
) 
4 6 8 14 (8.05
c
) 
2 6 7 13 (7.15
c
) 
5a 1 2 3 (1.34
d
) 
6a 1 2 3 (1.19
d
) 




Values given in parenthesis followed by different 
alphabets differ significantly with the application of 





ria of HCC development and progression. 
HCV genotyping of the 179 patients was performed 
using standard technique (Idrees et al., 2009). The pre-
dominant genotype was genotype 3 (3a = 56.18%, 3b = 
15.80%) followed by genotype 1 (9.24%), 4 (8.05%), 2 
(7.15%), 5a (1.34%) and 6a (1.19%), respectively (Table 
2). Most hepatitis C infections in Pakistan are caused by 
HCV genotypes 3a (56.18%), 3b (15.80%), followed by 1 
(9.24%), 4 (8.05%), 2 (7.15%), 5a (1.34%) and 6a 





Epidemiological studies in different countries of the world 
exhibit a wide variation in HCV prevalence pattern, 
though incidence of HCV development and progression is 
higher among less developed nations (Idrees, 2008; 
Idrees et al., 2009). Chronic HCV has been identified as 
the major risk factor for the development of HCC. Several 
viral and host factors linked with HCC development have 
been studied extensively in recent years (Farshapour et 
al., 2010). We found that longer life and male gender 
were significantly more linked with HCC development 
(Table 1). This association between HCC and donor age 
and gender was also observed in other countries 
(Tavares et al. 2004; Idrees et al., 2009). This suggests 
that older population with longer times of exposure to the 
various infection risk factors have a greater propensity of 
being victim of chronic HCV leading to HCC.  
All HCC patients had elevated level of serum bilirubin 
(> 14.2 µmol/L) and ALP (>150 IU/L), ALT (>60 IU/L) and 
AST (>62 IU/L). AFP (99.2%) and GGT (65.2%) levels 
were abnormal in patients suffering from HCC and it is a 
normal trend. Hepatic cirrhosis was found in 81% patients 
with HCC. All the patients were negative for anti-HIV 1. 
All HCC patients had past history of chronic HCV in-
fection. 21 of them also had cholecystitis. Load of peri-
pheral   HCV   RNA  varied  from  2.5  x  10
3 






copies/ml. We did not find significant difference (P<0.235) 
between HCV load in serum samples and tissue samples 
of the same HCC patients. Neither from PCR analysis nor 
from anti-bodies or serological records, could we find any 
etiological information about two patients, and it remained 
un-typed. They fell in the age range of 24 ± 10 years. 
This HCC infection did not follow general criteria of HCC 
development and progression as mentioned earlier. 
Several host and viral factors have been involved in the 
onset of HCC. Among the viral factors, it has been repor-
ted that the presence of HCV genotypes are among the 
risk factors for HCC. We found that older patients had 
HCC. This finding is consistent with earlier studies where 
it was reported that it took several years for the onset of 
HCC in HCV patients (Idrees et al. 2009). AFP elevation 
was observed in 99.2% patients with HCC, while cirrhosis 
was present in 81% cases (Table 1) among the HCC 
patients studied. Earlier studies reported that cirrhosis 
underlies HCC in more than 80% of all HCC patients 
(Fattovich et al., 2004). It has been suggested that any 
agent that leads to cirrhosis, may be considered as risk 
factors for the development of HCC. This risk is en-
hanced in those patients whose sera have increased 
levels of AFP (Idrees, 2008). There were 15 (8.37%) 
cases that were caused by past HCB infection and 
relapsed to HCV infection. Two of them died even when 
they were receiving interferon therapy. All others HCC 
patients were chronic HCV patients.  
HCV genotyping of the 179 patients was performed 
using standard technique (Idrees, 2008). In this study, we 
observed preponderance of infection by genotype 3 
(71.98%) among the rural patients in Faisalabad. The 
HCV genotype most commonly found throughout most of 
the urban population in Lahore, northern areas, southern 
and western areas of country was also found as geno-
type 3, with percentages varying from 71.0 to maximum 
of 90% (Ahmed et al. 2007; Hakim et al. 2008; Hamid et 
al. 2004; Waheed et al. 2009). These authors reported 
that 51% of HCV patients had genotype 3a; 24% patients 
had a coinfection of 3a/3b and 16% predominantly had 
3b. Afridi et al. (2009) also reported 50% preponderance 
of genotype 3a followed by 3b and 1a. The most exhaust-
tive study of HCC was conducted by Idrees et al. (2009) 
on urban HCC patients. They found that 40.9, 15.66, 9.63 
and 2.4% among the 145 HCC patients had 3a, 3b, 1a 
and 1b, respectively. Based on these results and those of 
our study, we can conclude that most hepatitis C infec-
tions in Faisalabad region’s rural population were due to 
genotype 3, with the highest proportion (80%) also found 
in Bahawalpur (Qazi et al. 2006). This result implies that 
patients infected with HCV in this area should preferen-
tially be treated with a specific clinical protocol for 










factor for the spread of HCC in Pakistan as already been 
reported for Italy, Japan and Spain. All these HCC cases 
are HCV-related and no case was linked with other types 
of viruses. HCV genotype 3a was the predominant geno-
type in 55.3% cases and is a major risk factor for the 
development of HCC and may cause increased onco-
genecity in our population. HCC was linked with liver 
cirrhosis (81%). It was also found that treatment with 
interferon did not stop the progression of HCC. It 
demands immediate attention of the concerned autho-
rities to take maximum proper preventive measures to 
stop its transmission and progression in the general 
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